Key Highlights
- Shares of Hims & Hers (HIMS) skyrocketed more than 44% during premarket hours Monday following a Bloomberg report about a Novo Nordisk distribution agreement
- An official announcement regarding the collaboration could be made as soon as Monday
- This partnership represents a dramatic shift after Novo Nordisk filed a lawsuit against Hims in February concerning a generic version of its oral Wegovy medication
- Leerink’s Michael Cherny described the news as “both a surprise and an unabashed positive for HIMS’ stock” while maintaining his Market Perform rating
- Morgan Stanley analyst Craig Hettenbach noted the partnership might reduce legal and regulatory uncertainties that have pressured the heavily shorted shares
Shares of Hims & Hers Health (HIMS) exploded by over 44% during premarket trading Monday following a Bloomberg report indicating Novo Nordisk will distribute its weight-loss medications via the Hims telehealth platform.
According to the report, the companies may formally unveil the partnership as early as Monday. The revelation propelled HIMS shares significantly higher, while Novo’s Copenhagen-traded shares gained approximately 1%.
Hims & Hers Health, Inc., HIMS
The surge represents a dramatic reversal for shares that had plummeted roughly 51% year-to-date prior to Monday’s session.
Under the agreement, Novo’s obesity medications — including treatments associated with its Ozempic and Wegovy franchises — would become available through the Hims platform. This represents a significant pivot considering the recent antagonism between the two organizations.
Novo Nordisk initiated legal action against Hims in February after the telehealth provider introduced a generic alternative to Novo’s oral Wegovy weight-loss medication. The pharmaceutical giant claimed the offering violated patents protecting its bestselling treatments.
That legal confrontation was merely the most recent conflict. Novo had previously challenged Hims for allegedly promoting compounded alternatives to its medications even after their relationship had deteriorated.
What Analysts Are Saying
Michael Cherny from Leerink characterized the news as “both a surprise and an unabashed positive for HIMS’ stock.” He suggested the agreement might prevent what appeared to be “a protracted legal process that could include a full trial.”
However, Cherny refrained from upgrading his outlook. “Even with this positive news, we do not see this as a clearing event for HIMS to fully recapture its growth potential,” he noted, maintaining his Market Perform recommendation on the shares.
Craig Hettenbach from Morgan Stanley expressed comparable sentiment. He indicated the collaboration could alleviate a major concern surrounding HIMS — the regulatory and legal uncertainties connected to its weight-loss segment.
Hettenbach observed that “any reduction in those risks could lead to a strong reband in the heavily shorted stock.”
The Compounded Drug Controversy
Telehealth providers like Hims gained the ability to distribute more affordable compounded alternatives of Novo and Eli Lilly weight-loss treatments during supply shortage periods when branded products were unavailable.
Those supply constraints have now been resolved. Regulatory authorities anticipated compounding activities would cease, but certain telehealth platforms continued operations by modifying dosages or formulations to distinguish their offerings from branded alternatives.
This strategy placed Hims directly in Novo’s litigation sights earlier this year.
The reported arrangement, once verified, would fundamentally transform this dynamic — converting Hims from a direct competitor into an authorized distribution channel for Novo’s branded medications.
Novo’s Copenhagen-listed shares advanced roughly 1% on the developments as of early Monday trading.
